Evidence map›Paper›PMID 41483435›Full record

ArticleDigestive diseases and sciences2026

Trends in Length of Stay, Steroid Use and Colectomy Rates in Patients Admitted with Acute Severe Ulcerative Colitis: The Impact of Accelerated and Intensified Infliximab Dosing.

Ryan Bartlett, Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, Melissa Chew, Sarah Lucas, Ayushi Chauhan, Leya Nedumannil, Rebecca Pearce, Rifa Rawoof, Mani Suleiman and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Advances in the clinical management of acute severe ulcerative colitis].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ryan BartlettDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Mustafa MohamedrashedDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Saiumaeswar YogakanthiDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Melissa ChewDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Sarah LucasDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Ayushi ChauhanDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Leya NedumannilDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Rebecca PearceDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Rifa RawoofDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Mani SuleimanDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Robert D LittleDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Diana LewisDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Soleiman KashkooliDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia.
Mayur GargDepartment of Gastroenterology, Northern Health, 185 Cooper Street, Epping, Melbourne, VIC, 3076, Australia. mayur.garg@unimelb.edu.au.ORCID http://orcid.org/0000-0002-9149-3589

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe optimal dose of infliximab in patients with acute severe ulcerative colitis (ASUC) with inadequate intravenous steroid response remains unclear. We aimed to evaluate infliximab dosing on outcomes of patients with ASUC.

methodsA retrospective review of medical records was performed for patients with ASUC; grouped by cumulative infliximab dose administered during the first 14 days: standard (5 mg/kg) or intensified/accelerated (10-15 mg/kg or ≥ 20 mg/kg). Outcomes included prescribing patterns over time, length of stay, and 12-month readmission, colectomy and steroid requirement, as well as safety.

resultsOf 213 patients admitted with UC, 147 met criteria for ASUC. 83 patients (28 [34%] female, median age 33 [IQR 24.5-48] years) received infliximab (29 [35%] 5 mg/kg, 35 [42%] 10-15 mg/kg and 19 [23%] ≥ 20 mg/kg). Intensified/accelerated infliximab dosing (≥ 10 mg/kg) increased from 2016-2019 (26%) to 2020-2024 (76.5%) (p = 0.015), correlating with overall reduction in 12-month colectomy rates from 13.6% in 2016-2019 to 2.5% in 2020-2024 (p = 0.014). Disease severity was higher in patients receiving intensified/accelerated dosing. Median length of stay was shorter in those receiving 5 mg/kg and 10-15 mg/kg than ≥ 20 mg/kg (6 vs 11 days, p = 0.001). No difference was seen in colectomy or readmission rates or 30-day infective complications following different infliximab doses. 12-month steroid requirement was lower with following ≥ 20 mg/kg (median 1600 mg) than 5 mg/kg (1850 mg), p = 0.038.

conclusionIntensified/accelerated infliximab prescription in patients with ASUC increased over the past decade, correlating with reduced colectomy rates. Despite higher disease severity, colectomy and 12-month readmission rates were similar across dosage groups, with 12-month steroid requirement less after ≥ 20 mg/kg than 5 mg/kg.

Indexed as

ColectomyColitis, UlcerativeGastrointestinal AgentsInfliximabLength of StaySteroidsAcute DiseaseAdultFemaleHumansMaleMiddle AgedPatient ReadmissionRetrospective StudiesSeverity of Illness IndexTreatment OutcomeGastrointestinal AgentsInfliximabSteroidsAcute severe ulcerative colitisColectomyInfliximab therapyLength of Stay

Identifiers

PMID41483435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.